6826 (6826) Fair Value & Analysis

Healthcare · Market cap HK$3.5B

6 6826 6826 · HK

PriceHK$15.49

Fair ValueHK$27.31

Upside+76.3%

Quality53/100

Watch 6826 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$20.80 – HK$32.92

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −10.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$15.23 – HK$28.57 · fair‑value band HK$20.80 – HK$32.92 · the HK$15.49 price screens below the HK$27.31 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6826 (6826) currently trades at HK$15.49, while our model-based Fair Value estimate is HK$27.31 — implying the stock looks roughly 76.3% undervalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6826 generated revenue of HK$2.4B at a net margin of 9.8%. Revenue declined 7.6% year over year. It earns a return on equity of 3.4%. The balance sheet holds a net cash position of HK$2.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.4B

Revenue growth (YoY) -7.6%

Net margin 9.8%

Return on equity 3.4%

Free cash flow HK$446M FY2025

P/E ratio 12.5

More key figures

Operating margin 13.1%

EPS (TTM) HK$1.08

Dividend yield 6.5%

EPS growth (YoY) -17.9%

Net cash HK$2.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6826 reported revenue of HK$2.4B in FY2025 versus HK$1.8B in FY2021, a compound +8.7%/yr. Reported net income was HK$245M in FY2025, compounding −8.7%/yr from FY2021.

Revenue +8.7%/yr

FY21 HK$1.8B

FY22 HK$2.1B

FY23 HK$2.6B

FY24 HK$2.7B

FY25 HK$2.4B

Net income −8.7%/yr

FY21 HK$352M

FY22 HK$180M

FY23 HK$416M

FY24 HK$420M

FY25 HK$245M

Is 6826 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	4,803 MXN	-38%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,011,109 KRW	+1%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6826 (6826) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$27.31 versus a price of HK$15.49 — about +76% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 6826?

Our model-based fair value for 6826 is HK$27.31 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$15.49.

What is the quality score of 6826?

6826 has a Quality Score of 53/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6826 (6826)?

6826 reported trailing-twelve-month revenue of about HK$2.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6826?

The net profit margin of 6826 is about 9.8%, meaning it keeps roughly 9.8% of revenue as net income. Based on the latest reported figures.

Does 6826 pay a dividend?

6826 currently shows a dividend yield of about 6.53% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.